An editorial recently published in The BMJ discusses addresses 1 of the most commonly misunderstood biosimilar concepts: extrapolation.
In 2017, the European Society for Medical Oncology (ESMO) published its position paper on biosimilars for oncology prescribers. Since the paper's publication, both the FDA and the European Medicines Agency (EMA) have approved biosimilar versions of monoclonal antibodies to treat multiple cancer types, but misconceptions about biosimilars are still prevalent.
An editorial recently published in The BMJ discusses addresses 1 of the most commonly misunderstood biosimilar concepts: extrapolation. The authors define extrapolation as “the authorization of a biosimilar medicine for clinical indications of the reference medicine without the need to conduct clinical trials of the biosimilar medicine in those indications.” The crucial part in understanding the concept is to first acknowledge that extrapolation is a well-established regulatory and scientific principle that has been used well before the arrival of biosimilar medicines.
As an example, the authors explain that the principle of extrapolation is also applied after major changes in the manufacturing process of a biologic. When this kind of change takes place, the manufacturer is required by regulatory agencies to conduct a comprehensive comparability exercise to establish that the pre-manufacturing change and post-manufacturing change products are sufficiently similar. Clinical data are usually studied in 1 indication and extrapolated to the other indications, while taking into account all data generated by the comparability exercise.
The authors note that potential confusion around extrapolation may come about from the term itself. When utilized in mathematical terms, "extrapolation" refers to the projection of unknown values from trends in known data. However, when the term is applied to biosimilar medicines, extrapolation is based on the knowledge that the biosimilar medicine is similar to the reference in all critical quality attributes. In fact, Health Canada previously acknowledged the confusion around the terminology and consequently removed the term “extrapolation” from its biosimilar guidance in 2016.
The authors say that it is important to understand that extrapolation is undertaken from the reference to the biosimilar medicine—molecule to molecule—rather than from 1 indication in which the biosimilar medicine has been studied to other indications. Furthermore, each extrapolated indication needs to be scientifically justified and assessed by regulators.
“From regulatory and scientific viewpoints, the active substance of a biosimilar is just another version of the active substance of the reference medicine,” said the authors.
Reference
Krendyukov A, Schiestl M. Extrapolation concept at work with biosimilar: a decade of experience in oncology. Published February 6, 2018. Br Med J. doi:10.1136/ esmoopen-2017-000319.
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.